Drug Profile

KD 299

Alternative Names: KD-299; KD-299 5th generation - Nanjing KAEDI Biotech; KD-299^5th

Latest Information Update: 28 Feb 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

28 Feb 2024 No recent reports of development identified for preclinical development in Cancer in China (Parenteral)
15 Jan 2020 KD 299 is available for licensing as of 15 Jan 2020. http://www.cartbiomed.com/
01 Jan 2020 Preclinical trials in Cancer in China (Parenteral) before January 2020 (Nanjing KAEDI Biotech pipeline, January 2020)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com